Summary of Tonix Pharmaceuticals Holding (TNXP) Conference Call Company Overview - **Company Name**: Tonix Pharmaceuticals Holding Corp - **Ticker Symbol**: TNXP - **Recent Approval**: FDA approval for Onmya (cyclobenzaprine sublingual tablets) for treating fibromyalgia in adults on August 15, 2025 [2][4] - **Current Focus**: Launching Onmya and leveraging existing commercial infrastructure from previously marketed migraine drugs [2][3] Industry Insights - **Fibromyalgia Prevalence**: Approximately 10 million American adults are affected by fibromyalgia, with about 3 million diagnosed and treated [4][10] - **Diagnosis Challenges**: On average, it takes about six years for patients to receive a fibromyalgia diagnosis, highlighting a significant unmet need in timely treatment [10][18] - **Evolving Understanding**: Fibromyalgia is increasingly recognized as a nociplastic syndrome, with symptoms including widespread pain, fatigue, sleep disturbances, and cognitive issues [10][12] Onmya Product Insights - **Mechanism of Action**: Onmya is designed to target non-restorative sleep and pain, differentiating itself from existing therapies by bypassing hepatic metabolism and reducing the major metabolite, norcyclobenzaprine [22][23] - **Comparison with Other Therapies**: Onmya is positioned as a first-in-class drug targeting fibromyalgia, with a potentially broader spectrum of effects compared to existing treatments like Lyrica and Cymbalta [25][26] - **Tolerability Profile**: Onmya is not DEA scheduled, which may enhance its prescription potential compared to Lyrica, which has lower prescribing rates due to its scheduling [28][29] Commercial Strategy - **Target Market**: Initial launch targets the 3 million diagnosed patients, with plans to expand to the larger population of 10 million [32][34] - **Sales Force Strategy**: Tonix plans to hire additional sales representatives and utilize a combination of internal and contract sales forces to effectively reach healthcare providers [34][38] - **Pricing Strategy**: Pricing for Onmya has not yet been announced, but factors include health economics related to fibromyalgia treatment costs and the potential benefits of non-opioid therapies [39][40] Additional Considerations - **Opioid Use in Fibromyalgia**: There is a significant off-label use of opioids for fibromyalgia, which is concerning as long-term use may worsen the condition [29][30] - **Patient Advocacy**: Many patients may be aware of their fibromyalgia but have not sought diagnosis due to dissatisfaction with current treatment options [35][36] This summary encapsulates the key points discussed during the conference call, providing insights into Tonix Pharmaceuticals' strategic direction, product differentiation, and the broader context of fibromyalgia treatment.

[Music] Hi. Hello. From what uh hearing from what you guys think about me, I sound like a very fun um energetic uh person to be around. Um, I am sorry in advance if this talk is not going to be as fun as you imagine it's going to be. Uh, because I don't think you all understand how much this moment matters to me because for the past few years I sort of disappeared. Not that the world was waiting. Not that any of you may have realized or not realized. But I did disappear. My family knows. A lot of my family ...